Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NARATRIPTAN vs ACUVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Acute treatment of migraine with or without aura in adults
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.
1 drop in the affected eye 4 times daily.
Terminal elimination half-life is approximately 5–6 hours (range 4–8 hours), supporting a twice-daily dosing interval for acute migraine treatment and allowing once-daily dosing for menstrual migraine prophylaxis.
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Hepatic via cytochrome P450 (CYP) enzymes, primarily CYP3A4, with minor contribution from other isoforms. Metabolites are inactive.
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Renal: ~50% (metabolites and unchanged drug); Fecal: ~30%; Biliary: minor; unchanged naratriptan accounts for <10% of urinary recovery.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
~29% bound, primarily to albumin.
>99% bound to plasma proteins, primarily albumin.
Approximately 2.4 L/kg (range 1.8–3.0 L/kg), consistent with extensive tissue distribution beyond plasma.
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
Oral: 74% (range 63–95%); subcutaneous: ~100% (but not marketed).
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
No dose adjustment recommended; however, use with caution in severe renal impairment (Cr Cl <15 m L/min) due to limited data.
No adjustment required. Drug is minimally systemically absorbed.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), maximum dose is 2.5 mg per day; do not exceed single dose of 2.5 mg.
No adjustment required. Drug is minimally systemically absorbed.
Safety and efficacy not established in patients under 18 years; no approved pediatric dosing guidelines.
Safety and efficacy in pediatric patients have not been established.
Use with caution due to potential for reduced hepatic and renal function; no specific dose adjustment recommended, but start at low end of dosing range (2.5 mg).
No specific dosage adjustment is recommended; use same dose as younger adults.
Naratriptan is contraindicated in patients with ischemic heart disease or coronary artery vasospasm due to risk of myocardial ischemia/infarction and cerebrovascular events.
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
Cardiac events: risk of myocardial ischemia, infarction, and arrhythmias,Cerebrovascular events: stroke, subarachnoid hemorrhage,Serotonin syndrome: especially with concomitant serotonergic drugs,Medication overuse headache: chronic use can lead to daily headaches,Severe hepatic impairment: reduce dose or avoid,Severe renal impairment: contraindicated
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Ischemic heart disease (angina, history of MI, silent ischemia),Coronary artery vasospasm (Prinzmetal's angina),History of stroke or transient ischemic attack,Uncontrolled hypertension,Hemiplegic or basilar migraine,Severe hepatic impairment (Child-Pugh C),Severe renal impairment (Cr Cl <15 m L/min),Concurrent use of ergotamine derivatives or other 5-HT1 agonists within 24 hours,Hypersensitivity to naratriptan or any component
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
No significant food interactions. However, grapefruit juice may theoretically increase naratriptan exposure via CYP1A2 inhibition; avoid concurrent intake of large quantities. Alcohol may exacerbate migraine symptoms and should be avoided during an attack.
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester unless benefit outweighs risk. Second/third trimester: limited data; use only if clearly needed.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
Unknown if excreted in human milk; M/P ratio not established. Due to low molecular weight (335.46 g/mol), excretion is possible. Caution advised; monitor infant for adverse effects (e.g., drowsiness, diarrhea).
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
No specific pharmacokinetic data in pregnancy. Increased plasma volume and renal clearance in pregnancy may reduce drug exposure; however, lack of safety data precludes dose adjustments. Use lowest effective dose for shortest duration.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
Naratriptan has a longer half-life (~6 hours) and higher oral bioavailability (70%) compared to sumatriptan, making it suitable for patients with prolonged migraine attacks or those requiring sustained relief. It is contraindicated in patients with a history of ischemic heart disease, cerebrovascular disease, or uncontrolled hypertension due to vasoconstrictive effects. Use within 4 hours of migraine onset for optimal efficacy; do not use for prophylaxis. Monitor for serotonin syndrome when co-administered with other serotonergic drugs.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
Take naratriptan at the first sign of migraine headache; do not use to prevent migraines.,Do not exceed one tablet (2.5 mg) within 24 hours; do not take more than 2 tablets in any 24-hour period.,Seek emergency medical attention if you experience chest pain, shortness of breath, or sudden severe abdominal pain after taking this medication.,Inform your doctor if you have heart disease, high blood pressure, liver or kidney problems, or if you are pregnant or breastfeeding.,Avoid using naratriptan within 24 hours of other triptans or ergotamine-containing medications.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
"Concurrent use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, with dapiprazole, an alpha-1 adrenergic receptor antagonist, may lead to additive vasoconstrictive effects on coronary, cerebral, and peripheral vasculature. This synergy increases the risk of severe adverse events such as myocardial ischemia, hypertension, or cerebrovascular complications due to unopposed vasoconstriction from naratriptan and potential reflex sympathetic activation from dapiprazole's alpha blockade. Particularly in patients with underlying cardiovascular risk factors, this combination can precipitate hypertensive crises or ischemic events."
"Concomitant use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, and clozapine, an atypical antipsychotic with potent 5-HT2A receptor antagonism, may lead to additive serotonergic effects, increasing the risk of serotonin syndrome. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients, especially those on higher doses or with other serotonergic agents, should be closely monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia."
"Concomitant use of naratriptan, a 5-HT1B/1D receptor agonist, with bromocriptine, a dopamine D2 receptor agonist and ergot alkaloid derivative, may result in additive vasoconstriction due to synergistic stimulation of serotonin and dopamine receptors on vascular smooth muscle. This can lead to an increased risk of hypertensive crises, coronary artery vasospasm, myocardial ischemia, or cerebral ischemia, particularly in patients with underlying cardiovascular disease. Additionally, both drugs can elevate serotonin levels centrally, potentially raising the risk of serotonin syndrome, characterized by agitation, hyperthermia, and neuromuscular abnormalities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NARATRIPTAN vs ACUVAIL, answered by our medical review team.
NARATRIPTAN is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.. ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NARATRIPTAN and ACUVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NARATRIPTAN is: 2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.. The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NARATRIPTAN and ACUVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NARATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester . ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.